PMS2 and mismatch repair cancer syndrome 1: Mismatch repair deficiency (MMR-D, defined as loss or inactivation of MLH1, MSH2, MSH3, MSH6, PMS2) was found in 2.1% of all sarcomas; these alterations were mono- or biallelic (Supplementary Fig. S4a).